Back

Lectin-like oxidized LDL receptor-1 (LOX-1) in cardiomyocytes (CMs) is involved in the pathogenesis of doxorubicin (DOX)-induced cardiomyopathy

29 August 2017 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Comorbidities in heart failure Cardiotoxicity of drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Takuma Aoyama

Kizawa Memorial Hospital, Minokamo (Japan)

5 More presentations in this session

Presentation thumbnail
Ischemic versus dilated cardiomyopathy - differences in clinical characteristics and prognosis depending on heart failure etiology.
Doctor A. Tyminska (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Atrial fibrillation or rapid ventricular response in patients with left ventricular dysfunction: which is relevant to the long-term clinical outcome?
Doctor G. Benfari (Verona, IT)
Abstract Slides
Presentation thumbnail
HYCHeF: a risk score to predict congestive heart failure incidence in hypertension. (based on 18795 individual patient data)
Doctor H. Le (Lyon, FR)
Abstract Slides
Presentation thumbnail
Intravenous iron therapy in acute decompensated heart failure patients with iron deficiency anaemia
Doctor A. Kamal (Cairo, EG)
Abstract Slides
Presentation thumbnail
Elevated potassium levels in patients with congestive heart failure: incidence and clinical outcomes. A Danish population based cohort study
Doctor R. Thomsen (Aarhus, DK)
Abstract Slides

Access the full session

Session thumbnail
Comorbidities in heart failure

The Event

Event poster

ESC Congress 2017

29 August 2017 15:35 CET
You may be interested in
thumbnail
Congress Presentation
Unveiling doxorubicin-induced cardiotoxicity: into the heart with single-cell resolution
20 June 2025
thumbnail
Webinar
Exercise, rehabilitation and preventive strategies in cardio-oncology
3 December 2025
thumbnail
Congress Presentation
Epirubicin promotes coronary endothelial senescence and dysfunction with induction of pro-inflammatory and pro-thrombotic responses: role of the AT1R/NADPH oxidases/SGLT2 pro-oxidant pathway
11 May 2026
thumbnail
Congress Presentation
Systemic H-FABP, hs-cTnT, hs-CRP and Monocyte-to-Lymphocyte ratio were significantly reduced by sacubitril/valsartan in doxorubicin-treated preclinical models through NLRP3-mTOR-AKT pathways
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources